European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV
- Contract spans 225 million initial doses and the option for an additional 180 million doses
- Upfront payment to support financing of advanced clinical development of CVnCoV, ramp-up of European manufacturing network and market supply preparations
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), reports the European Commission’s announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac´s mRNA-based COVID-19 vaccine candidate, CVnCoV.